ImmunityBio, Inc. (IBRX)

ImmunityBio, Inc. is trading at $10.51, up 6.05% on the session. The 50 day average sits at $8.17 and the 200 day at $7.32, which puts the stock in a uptrend. RSI is at 61.1, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $8.26 with resistance near $10.81, so that band frames the current range. Average daily movement is roughly $0.62, or about 5.9% of the share price, which is what any stop placement has to allow for. The overall health score of 78 out of 100 combines a trend score of 97, momentum of 88 and a risk score of 34.

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.